Related Experiment Video
Updated: May 26, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea
1Division of Hepatology, Seoul St Mary's Hospital, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. iychoi@catholic.ac.kr
Oncology
|January 4, 2012
Summary
This guideline details hepatocellular carcinoma (HCC) treatment in Korea, dividing care by Barcelona Clinic Liver Cancer (BCLC) stage. It outlines curative options for early HCC and noncurative strategies for intermediate and advanced stages.
Area of Science:
- Hepatology
- Oncology
- Clinical Practice Guidelines
Background:
- The 2009 Korean practice guideline for hepatocellular carcinoma (HCC) was updated based on clinical evidence.
- Treatment is stratified by Barcelona Clinic Liver Cancer (BCLC) staging into curative (early stage) and noncurative (intermediate and advanced stages).
Purpose of the Study:
- To outline the evidence-based treatment algorithm for HCC in Korea.
- To define treatment modalities for different stages of HCC, including curative and noncurative options.
Main Methods:
- The guideline categorizes HCC treatment based on BCLC staging.
- It reviews evidence for surgical resection, radiofrequency ablation, transarterial chemoembolization (TACE), liver transplantation (LT), systemic therapy, and radiation therapy (RT).
Main Results:
- Transarterial chemoembolization (TACE) is the primary treatment for intermediate stage HCC (BCLC-B) with Child-Pugh A cirrhosis.
- Sorafenib is the standard of care for advanced stage HCC (BCLC-C) unsuitable for locoregional therapies.
- Liver transplantation (LT) offers survival benefits for select Child-Pugh C patients with acceptable tumor burden.
Conclusions:
- Treatment decisions for HCC must be individualized based on BCLC stage, liver function (Child-Pugh score), and tumor burden.
- Further prospective randomized controlled trials (RCTs) are needed to establish the efficacy of radiation therapy (RT) for large-sized intermediate and advanced HCC.
